Deep 6 AI Has Been Acquired by Tempus

DEEP 6 AI   *Acquired by*   **TEMPUS**

138th	31st	12th
Pharma Services Deal	eClinical Transaction	Decentralized Trials Deal

Deep 6 AI Has Been Acquired by Tempus to Enhance AI-Driven Patient Recruitment and Qualification for Clinical Trials, Accelerating Drug Development and Trial Efficiency

The clinical trials industry is rapidly evolving, with approximately 80% of clinical trials experiencing delays or closures due to recruitment challenges. Traditional recruitment methods often struggle to identify eligible participants, leading to significant inefficiencies. However, the integration of artificial intelligence (AI) in clinical trials is projected to expand substantially, with the AI in clinical trials market expected to grow from $1.58 billion in 2023 to around $20.16 billion by 2033. AI-powered qualification technology can analyze vast amounts of structured and unstructured data—such as electronic health records and physician notes—to match patients with trials in real time. This innovation not only reduces trial delays but also enhances patient diversity and increases the success rate of drug development by ensuring faster and more precise recruitment.

Deep 6 AI, headquartered in Pasadena, California, specializes in clinical data software that accelerates patient recruitment for clinical trials. Using artificial intelligence and natural language processing, their platform analyzes unstructured medical data, such as physician notes, to match patients with appropriate trials more efficiently. By transforming fragmented records into unified patient profiles, Deep 6 enables healthcare providers, researchers, and patient access organizations to expedite the identification of qualified patients for clinical trials

Tempus AI, a publicly traded leader in AI-driven healthcare solutions, specializes in leveraging large datasets—including genomic, clinical, and molecular information—to advance precision medicine and clinical trial efficiency. The acquisition of Deep 6 AI strengthens Tempus's position in the drug development market by enhancing its ability to curate and analyze unstructured healthcare data. By integrating Deep 6's AI technology, Tempus gains deeper access to patient eligibility data across diverse sources, including lab results, surgical history, and medication records. The combined entity will improve lead qualification for clinical trials and enable faster and more precise patient matching.

Crosstree played a pivotal role in facilitating the transaction as an advisor to Deep 6 AI. Initially engaged to ensure a thorough market assessment and explore all strategic opportunities, Crosstree quickly connected Deep 6 with the right potential acquirers. Leveraging its deep market intelligence, network, and strong industry relationships, Crosstree orchestrated one-on-one executive discussions to assess strategic fit and drive an expedited process. The result was a swift and efficient transaction, **closing in just over 30 days.** This deal underscores Crosstree's ability to create market certainty and maximize value for its clients in the pharma services and healthcare technology sectors.

"Crosstree's deep domain and technical expertise helps clients develop and execute growth strategies that maximize value creation synergies and create differentiated value propositions for clients"

Shane Senior
Director
shane.senior@crosstreecapital.com

813-774-4755

CROSSTREE

Crosstree's experts are specialists in the nuances of the health sciences, prioritizing corporate core values and providing:

| Deep analytics of capabilities and gaps | Systemized tactical strategies and a road map to success | Engaged experts in market analysis, financials, and premium valuations | Targeted and qualified prospects | Up-to-date industry trend analysis and forecasting |

Meeting the needs of both the buyer and the seller by the numbers and beyond is Crosstree's specialty.

About Deep 6 AI

Deep 6 AI is the leader in precision research software, enabling healthcare organizations and life sciences companies to de-risk trials, accelerate recruitment, and generate real-world evidence with speed and precision. Its AI-powered software precisely matches patients to clinical trials by mining real-time structured and unstructured electronic medical record data across its ecosystem of 1K+ research facilities, including 18 academic medical centers, 11 NCI-Designated Cancer Centers, and 3 NCI Community Oncology Research Programs.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world's largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data.

Other Recent Pharma Services Transactions: